Cargando…
Osteogenesis imperfecta—pathophysiology and therapeutic options
Osteogenesis imperfecta (OI) is a rare congenital disease with a wide spectrum of severity characterized by skeletal deformity and increased bone fragility as well as additional, variable extraskeletal symptoms. Here, we present an overview of the genetic heterogeneity and pathophysiological backgro...
Autores principales: | Etich, Julia, Leßmeier, Lennart, Rehberg, Mirko, Sill, Helge, Zaucke, Frank, Netzer, Christian, Semler, Oliver |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7427672/ https://www.ncbi.nlm.nih.gov/pubmed/32797291 http://dx.doi.org/10.1186/s40348-020-00101-9 |
Ejemplares similares
-
TAPT1—at the crossroads of extracellular matrix and signaling in Osteogenesis imperfecta
por: Etich, Julia, et al.
Publicado: (2023) -
Individualized treatment with denosumab in children with osteogenesis imperfecta – follow up of a trial cohort
por: Hoyer-Kuhn, Heike, et al.
Publicado: (2019) -
Two years’ experience with denosumab for children with Osteogenesis imperfecta type VI
por: Hoyer-Kuhn, Heike, et al.
Publicado: (2014) -
Personalized medicine in patients with Osteogenesis imperfecta
por: Semler, Oliver, et al.
Publicado: (2014) -
Safety and efficacy of denosumab in children with osteogenesis imperfecta - a first prospective trial
por: Hoyer-Kuhn, H., et al.
Publicado: (2016)